Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Equities researchers at Leerink Partnrs reduced their FY2026 EPS estimates for shares of Voyager Therapeutics in a research report issued on Wednesday, April 16th. Leerink Partnrs analyst L. Nsongo now anticipates that the company will post earnings per share of ($0.62) for the year, down from their prior forecast of ($0.49). The consensus estimate for Voyager Therapeutics' current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Voyager Therapeutics' FY2027 earnings at ($1.36) EPS.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.24). Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $4.39 million for the quarter, compared to the consensus estimate of $16.58 million. During the same quarter in the previous year, the company posted $1.25 earnings per share.
Other analysts also recently issued reports about the company. Canaccord Genuity Group lowered their target price on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, March 13th. HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. Wedbush restated an "outperform" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Finally, Wells Fargo & Company set a $10.00 price objective on Voyager Therapeutics and gave the stock an "overweight" rating in a research note on Wednesday, March 12th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $13.97.
Get Our Latest Analysis on VYGR
Voyager Therapeutics Trading Up 4.2 %
Shares of NASDAQ VYGR traded up $0.14 during midday trading on Friday, hitting $3.51. The company's stock had a trading volume of 175,601 shares, compared to its average volume of 453,291. The business's 50 day moving average is $3.70 and its two-hundred day moving average is $5.26. Voyager Therapeutics has a 12-month low of $2.75 and a 12-month high of $9.55. The firm has a market cap of $193.78 million, a P/E ratio of 4.94 and a beta of 1.02.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the company. Cubist Systematic Strategies LLC acquired a new position in shares of Voyager Therapeutics during the fourth quarter worth $29,000. Tower Research Capital LLC TRC grew its stake in Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock worth $31,000 after buying an additional 3,077 shares during the last quarter. Picton Mahoney Asset Management raised its stake in Voyager Therapeutics by 71.1% in the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock valued at $33,000 after buying an additional 2,444 shares during the last quarter. Oxford Asset Management LLP acquired a new stake in Voyager Therapeutics in the fourth quarter worth about $60,000. Finally, Tema Etfs LLC purchased a new stake in shares of Voyager Therapeutics during the fourth quarter worth about $85,000. Hedge funds and other institutional investors own 48.03% of the company's stock.
Insider Buying and Selling
In other Voyager Therapeutics news, CEO Alfred Sandrock sold 10,885 shares of the stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total transaction of $37,335.55. Following the completion of the sale, the chief executive officer now directly owns 430,931 shares of the company's stock, valued at approximately $1,478,093.33. This represents a 2.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.53% of the stock is currently owned by company insiders.
About Voyager Therapeutics
(
Get Free Report)
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
Featured Articles
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
